BPMC Projected Dividend Yield

Blueprint Medicines Corp ( NASDAQ : BPMC )

Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders. Co. delivers its approved medicines, AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO® (pralsetinib), to patients in the U.S. and Europe, and it is globally developing multiple programs for systemic mastocytosis lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Co. is developing a portfolio of investigational EGFR inhibitors such as BLU-945, BLU-701, BLU-525 and BLU-451, to address a range of common and uncommon epidermal growth factor receptor activating mutations, including exon 19 deletions, the L858R mutation and exon 20 insertions.

20 YEAR PERFORMANCE RESULTS